Compare Crispr Therapeutics AG (CRSP) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Philip Morris International Inc. — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Philip Morris International Inc. trades at $176.99 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 55.2× Crispr Therapeutics AG's market cap, and Philip Morris International Inc. pays a 3.34% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PM | |
|---|---|---|
Market Cap | $4.97B | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $191.86 |
52-Week Low | $44.34 | $144.33 |
Enterprise Value | $3.32B | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Philip Morris International (PM) trades at $180.19, down 0.79% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $194.00. The company reported strong Q1 2026 EPS of $1.96, beating expectations, and maintains robust profitability with a 26.74% net income margin. Recent news includes a $500 million impairment charge in Q2 2026 and CFO succession plans, while cash flow trends show stable operations.
The stock presents a favorable risk-reward profile with upside to analyst targets, driven by earnings beats and brand strength, though risks include currency volatility, regulatory pressures, and consumer spending constraints highlighted in recent Reuters and WSJ reports. Long-term investors may find value in its dividend yield and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
